Tag

##HariKiranChereddi

Explore articles tagged with #HariKiranChereddi

Active Filters:
Tag: #HariKiranChereddi
Clear All
A New Chapter in Europe
Business & Growth

A New Chapter in Europe

HRV Pharma has entered the European finished formulations market through its acquisition of Germany-based Phatebo. The move gives HRV an established pharmaceutical business with wholesale authorisation, good distribution practice systems and an existing customer base, complementing its global API portfolio.

Two Layers, One Value Chain
Business & Growth

Two Layers, One Value Chain

HRV Pharma is expanding across two layers of the pharmaceutical value chain through its acquisition of Phatebo GmbH. The combination brings together HRV's global API partner network and Phatebo's licensed European clinical trial supply and pharmaceutical distribution capabilities, while retaining the asset-light business model.

Into Clinical Trial Supply
Business & Growth

Into Clinical Trial Supply

HRV Pharma has expanded beyond APIs into clinical trial supply through its acquisition of Germany-based Phatebo. The company sources comparator, investigational and ancillary medicines for pharmaceutical companies and CROs worldwide, bringing HRV into a segment where reliability, traceability and timely delivery are essential.

A Foray Into European Markets
Business & Growth

A Foray Into European Markets

HRV Pharma is expanding into European markets through the planned acquisition of Germany-based Phatebo GmbH. The deal provides an entry into finished formulations, clinical trial supply and established pharmaceutical distribution capabilities, including a German wholesale authorisation and long-standing relationships with clinical trial sponsors.

Beyond APIs, Into Finished Formulations
Business & Growth

Beyond APIs, Into Finished Formulations

HRV Pharma is expanding beyond APIs into finished formulations through its acquisition of a 100% equity stake in Germany-based Phatebo. The acquisition marks a significant step in HRV's growth, giving the company its first finished formulations business and a licensed operating presence in Germany, while opening new opportunities in the European pharmaceutical market.

Two Bets on Complex Molecules, One Asset Light Model
API Manufacturing

Two Bets on Complex Molecules, One Asset Light Model

HRV Pharma is planning a ₹150 crore investment in peptides and high-potency APIs through a dedicated peptide programme and a joint venture focused on specialised oncology molecules. Both initiatives follow the company's asset-light model, retaining intellectual property, regulatory assets and commercial rights while working with specialist manufacturing partners.

Can Asset-Light Manufacturing Make Pharma Capacity Expansion Faster, More Flexible & Scalable? | Siliconindia
Industry News

Can Asset-Light Manufacturing Make Pharma Capacity Expansion Faster, More Flexible & Scalable? | Siliconindia

Hari Kiran Chereddi, Founder, MD & CEO, HRV Pharma, explores how asset-light manufacturing can help pharmaceutical companies build greater flexibility, scalability and efficiency into their manufacturing strategies.

India’s Race for the CDMO Crown | Express Pharma
Industry News

India’s Race for the CDMO Crown | Express Pharma

HRV Pharma Founder, MD & CEO Hari Kiran Chereddi shares insights in Express Pharma on India’s opportunity to become a strategic global CDMO partner through specialised capabilities, regulatory strength, scientific expertise and reliable execution.

HRV Pharma Bets ₹150 Crore on Peptides & High-Potency Oncology APIs | Mint
Industry News

HRV Pharma Bets ₹150 Crore on Peptides & High-Potency Oncology APIs | Mint

HRV Pharma is investing around ₹150 crore in peptides and high-potency oncology APIs, expanding specialised manufacturing capabilities through an asset-light model and strategic manufacturing partnerships.

Why Pharma Needs Smarter Decision-Making, Not Just More Digital Systems
Industry News

Why Pharma Needs Smarter Decision-Making, Not Just More Digital Systems

CEO Hari Kiran and CIO Sowjanya Varma in Express Pharma on why pharma’s next advantage lies in reasoning rather than more systems - and how RIKO™ shifts compliance from retrospective to predictive.

Building the Next Pipeline of Specialty APIs
Industry News

Building the Next Pipeline of Specialty APIs

HRV Pharma and Haleos Labs have entered into a multi-year strategic partnership to accelerate the development and GMP manufacturing of specialty APIs for regulated and semi-regulated markets.

Centre to Require Pharma to Distinguish Biologics from Synthetics | Mint
Industry News

Centre to Require Pharma to Distinguish Biologics from Synthetics | Mint

India’s proposed amendments to the Drugs Rules, 1945 could require pharmaceutical companies to clearly distinguish biological medicines from synthetic drugs, with implications for classification, traceability, quality and regulatory oversight.

India’s Pharma Industry Goes Digital
Industry News

India’s Pharma Industry Goes Digital

Digital transformation is reshaping pharmaceutical manufacturing in India, with technologies such as MES, electronic batch records, LIMS, digital twins, predictive analytics and AI helping strengthen compliance, data integrity and operational efficiency.

The New Growth Blueprint for APIs | BW Healthcare World
Industry News

The New Growth Blueprint for APIs | BW Healthcare World

The API industry is rethinking how manufacturing capacity and supply chains are structured, with manufacturing networks offering a more resilient approach through qualified partners, regulatory ownership and greater visibility.

From Manufacturing Scale to Institutional Intelligence
Artificial Intelligence

From Manufacturing Scale to Institutional Intelligence

The pharmaceutical industry's competitive edge is evolving from manufacturing capacity to institutional intelligence. Indian Pharma Post explores how HRV Pharma's RIKO uses seven years of proprietary operational data to assess risks, accelerate supplier qualification and support smarter pharmaceutical decision-making.

The Question That Built RIKO
Artificial Intelligence

The Question That Built RIKO

Why do preventable pharmaceutical problems keep recurring years after key decisions are made? Digital Health News explores how HRV Pharma's RIKO uses seven years of operational workflows and ten federated reasoning models to identify risks earlier, accelerate supplier qualification and support faster pharmaceutical decision-making.

One System for Both Sides of Pharma
Artificial Intelligence

One System for Both Sides of Pharma

HRV Pharma's RIKO is designed to bridge the gap between pharmaceutical manufacturers and customers. Drawing on millions of proprietary decisions across 55 countries, the AI-native platform supports faster partner qualification, transparent enquiry matching and early risk assessment across the pharmaceutical value chain.

Catching Risk Before It Becomes a Recall
Artificial Intelligence

Catching Risk Before It Becomes a Recall

In the pharmaceutical industry, identifying risks early can help prevent costly quality failures and recalls. PharmaClick explores how HRV Pharma's RIKO platform uses AI-driven pharmaceutical intelligence to assess chemistry risks, nitrosamine potential, supplier reliability and regulatory history before commitments are made.

RIKO by the Numbers
Artificial Intelligence

RIKO by the Numbers

Millennium Newsroom highlights the reported results of RIKO, HRV Pharma's AI-native pharmaceutical operating system. From 94% predictive accuracy in early nitrosamine risk assessments to 85% faster supplier qualification and commercial enquiry screening in under two seconds, RIKO applies pharmaceutical decision intelligence to real business challenges.

Meet RIKO, Built From Seven Years of Pharma Decisions
Artificial Intelligence

Meet RIKO, Built From Seven Years of Pharma Decisions

HRV Pharma has launched RIKO, an AI-native pharmaceutical operating system built on more than seven years of industry decisions. Drawing on insights from a network of 50+ FDA and EU GMP certified partners and customers across 55 countries, RIKO brings together AI-driven reasoning to support pharmaceutical sourcing, risk assessment and supplier qualification.

HRV Pharma Introduces RIKO™, India’s First AI-Native Pharmaceutical Operating System
Industry News

HRV Pharma Introduces RIKO™, India’s First AI-Native Pharmaceutical Operating System

RIKO™ is a self-learning reasoning engine built on seven years of proprietary pharmaceutical decisions across 50+ GMP-certified partners in 55 countries.

Trust Isn't a Feeling. It's a System.
Business & Growth

Trust Isn't a Feeling. It's a System.

How can a pharmaceutical company maintain quality without owning its manufacturing plants? HRV Pharma builds trust through standardised audits, real-time performance tracking and continuous visibility across 53 partners, helping identify issues before they become shipment or regulatory problems.

Not a Capacity Problem, a Utilisation Problem
API Manufacturing

Not a Capacity Problem, a Utilisation Problem

When Hari Kiran Chereddi founded HRV Pharma in 2016, he saw an opportunity to address underutilised pharmaceutical manufacturing capacity in India. In this ET Now interview, he explains HRV's asset-light model, its quality assurance systems across 53 sites, and its ambition to reach ₹1,000 crore while remaining debt free.

What Indian Pharma Is Really Buying
Business & Growth

What Indian Pharma Is Really Buying

Sun Pharma's $11.75 billion acquisition of Organon highlights a broader shift in the Indian pharmaceutical industry. Featuring insights from industry leaders, including HRV Pharma's Hari Kiran Chereddi, BioSpectrum explores the growing importance of brand value, specialty portfolios, biosimilars and access to regulated global markets.

₹400+ Crore Pharma Business Without a Factory
Industry News

₹400+ Crore Pharma Business Without a Factory

Business Standard explores HRV Pharma’s asset-light model, which combines regulatory assets, drug master files and customer relationships with a network of 53 manufacturing partners to build pharmaceutical scale without owning manufacturing facilities.

From Manufacturing to “Drug Visas”: How HRV Pharma Is Redefining Pharma Value Creation
Industry News

From Manufacturing to “Drug Visas”: How HRV Pharma Is Redefining Pharma Value Creation

HRV Pharma is redefining pharma economics by turning regulatory filings (DMFs) into scalable global assets—shifting value from manufacturing to compliance and market access.

Why the Future of Drug Development Begins Before Manufacturing
Industry News

Why the Future of Drug Development Begins Before Manufacturing

HRV Pharma CEO Hari Kiran Chereddi explains why drug development success is now determined before manufacturing, driven by data, predictive analytics, and strategic decision-making.

Future of Pharma: From Factories to Platform-Driven Models
Industry News

Future of Pharma: From Factories to Platform-Driven Models

HRV Pharma CEO Hari Kiran Chereddi shares insights on how platform-driven models are transforming pharma from factory-led systems to intelligent, network-based ecosystems.

HRV Pharma Partners with Shodhana Laboratories to Accelerate Next-Gen API Development
Industry News

HRV Pharma Partners with Shodhana Laboratories to Accelerate Next-Gen API Development

HRV Pharma partners with Shodhana Laboratories to accelerate next-generation API development, combining AI-enabled virtual manufacturing with precision chemistry and global regulatory execution.

How HRV Pharma’s Virtual Model Helps Solve America’s Drug Shortage Crisis
Industry News

How HRV Pharma’s Virtual Model Helps Solve America’s Drug Shortage Crisis

HRV Pharma’s capital‑efficient virtual pharmaceutical model is helping address America’s drug shortage crisis by linking underutilized global manufacturing capacity with regulatory strength to ensure consistent API supply.

HRV Pharma Redefines India’s Bulk Drug Business with a Virtual Pharma Model
Industry News

HRV Pharma Redefines India’s Bulk Drug Business with a Virtual Pharma Model

Fortune India features HRV Pharma for pioneering a capital‑efficient virtual pharma model that is transforming India’s bulk drug and API ecosystem through speed, compliance, and global regulatory execution.

Indian Biosimilars on the Global Stage: HRV Pharma CEO's Insights in Express Pharma
Industry News

Indian Biosimilars on the Global Stage: HRV Pharma CEO's Insights in Express Pharma

India's rise in biosimilars & biologics. Full clipping + insights included.